AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Expected to Announce Quarterly Sales of $1.77 Million

Equities research analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $1.77 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings. The lowest sales estimate is $450,000.00 and the highest is $3.08 million. AVEO Pharmaceuticals posted sales of $430,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 311.6%. The firm is expected to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that AVEO Pharmaceuticals will report full-year sales of $11.05 million for the current fiscal year, with estimates ranging from $3.11 million to $24.30 million. For the next fiscal year, analysts forecast that the company will report sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.



Several equities analysts recently weighed in on the stock. National Securities reissued a “sell” rating and issued a $5.00 target price on shares of Oxford Square Capital in a research note on Thursday, March 28th. Zacks Investment Research cut shares of HEXO from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. AVEO Pharmaceuticals has an average rating of “Hold” and a consensus price target of $1.96.

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its position in shares of AVEO Pharmaceuticals by 50.4% during the fourth quarter. Rhumbline Advisers now owns 138,271 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 46,307 shares during the period. New York State Common Retirement Fund increased its position in shares of AVEO Pharmaceuticals by 261.3% during the fourth quarter. New York State Common Retirement Fund now owns 248,600 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 179,800 shares during the period. BlackRock Inc. increased its position in shares of AVEO Pharmaceuticals by 3.3% during the fourth quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock worth $11,773,000 after acquiring an additional 236,822 shares during the period. Bank of New York Mellon Corp increased its position in shares of AVEO Pharmaceuticals by 28.0% during the fourth quarter. Bank of New York Mellon Corp now owns 423,673 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 92,663 shares during the period. Finally, Northern Trust Corp increased its position in shares of AVEO Pharmaceuticals by 3.0% during the fourth quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock worth $1,882,000 after acquiring an additional 34,164 shares during the period. 28.33% of the stock is owned by hedge funds and other institutional investors.

Shares of AVEO traded down $0.01 during mid-day trading on Friday, hitting $0.71. 1,959,940 shares of the company’s stock were exchanged, compared to its average volume of 3,026,099. The firm has a market capitalization of $114.12 million, a P/E ratio of -3.74 and a beta of 0.88. AVEO Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $3.59. The stock has a 50-day moving average of $0.72.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: Beta

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.